HUTCHMED (China) Ltd HCM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 274.00
- Day Range
- GBX 279.13–290.00
- 52-Week Range
- GBX 190.40–353.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 243.52 Bil
- Volume/Avg
- 159,094 / 87,128
Key Statistics
- Price/Earnings (Normalized)
- 30.87
- Price/Sales
- 4.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.13%
Company Profile
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Value
- Total Number of Employees
- 1,970
- Website
- https://www.hutch-med.com
Comparables
Valuation
|
Metric
|
HCM
|
ZURA
|
02171
|
|---|---|---|---|
Price/Earnings (Normalized) | 30.87 | — | — |
Price/Book Value | 4.16 | 1.66 | 1.56 |
Price/Sales | 4.01 | — | 347.20 |
Price/Cash Flow | 20.79 | — | — |
Price/Earnings
HCM
ZURA
02171
Financial Strength
|
Metric
|
HCM
|
ZURA
|
02171
|
|---|---|---|---|
Quick Ratio | 2.39 | 12.50 | 9.12 |
Current Ratio | 2.61 | 12.57 | 9.47 |
Interest Coverage | — | — | −159.86 |
Quick Ratio
HCM
ZURA
02171
Profitability
|
Metric
|
HCM
|
ZURA
|
02171
|
|---|---|---|---|
Return on Assets (Normalized) | −3.30% | −20.26% | −29.55% |
Return on Equity (Normalized) | −5.62% | −29.67% | −39.55% |
Return on Invested Capital (Normalized) | −5.05% | −30.68% | −38.18% |
Return on Assets
HCM
ZURA
02171
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Hcfpvddmw | Hxzw | $88.3 Bil | |||
| Merck KGaA ADR
MKKGY
| Ykrmygdb | Bvpnxjb | $78.0 Bil | |||
| Haleon PLC ADR
HLN
| Mzvcsvtx | Nmmn | $48.4 Bil | |||
| Viatris Inc
VTRS
| Ngmknbkc | Dcqzm | $13.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Fwzrcvs | Wqyn | $13.5 Bil | |||
| Catalent Inc
CTLT
| Kjmxykdp | Rgmflz | $10.9 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Ypbrvxbjl | Vthfjsm | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Gfgyksd | Lqxv | $3.5 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Qwmzplxtj | Wnjp | $2.5 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Rzxjwhhc | Yhf | $2.3 Bil |
United States